Only Korean firm to present on-site; cenobamate surpasses 300,000 cumulative prescriptions and launches in South Korea and Japan; opicalmib added to CNS lineup; next-generation oncology modalities and 'East-West Bridge' model unveiled

SK Biopharm President Lee Dong-hoon presents at the Jefferies Global Healthcare Conference, Europe's largest biotech investment event, in London on Tuesday (local time). [SK Biopharm]
SK Biopharm President Lee Dong-hoon presents at the Jefferies Global Healthcare Conference, Europe's largest biotech investment event, in London on Tuesday (local time). [SK Biopharm]

SK Biopharm attended the Jefferies Global Healthcare Conference in London — Europe's largest pharmaceutical and biotech investment event — for the fourth consecutive year, unveiling its growth strategy for its flagship product and new business expansion.

The company said Wednesday it participated in the conference, held in London from Monday through Thursday (local time), and was the only South Korean pharmaceutical or biotech firm to deliver an on-site presentation.

SK Biopharm President Lee Dong-hoon took the stage Tuesday to present the performance of cenobamate — an innovative epilepsy drug marketed in the United States as Xcopri — and the company's medium-to-long-term growth roadmap. Driven by expanding prescriptions in the US market, cenobamate surpassed 300,000 cumulative patients worldwide as of September. The drug completed its Northeast Asian rollout after launching commercially in China in March and entering South Korea and Japan this month, and has also begun a phased entry into Latin American markets including Peru, Chile and Brazil.

To manage cenobamate's lifecycle, SK Biopharm is pursuing expanded indications and age groups beyond the current adult partial-onset seizure indication — targeting primary generalized tonic-clonic seizures in patients aged 12 and older and partial-onset seizures in pediatric patients — while accelerating development of new formulations such as an oral suspension.

The company is also moving to diversify its central nervous system portfolio. Opicalmib (BHV-7000), an epilepsy drug candidate in-licensed from Biohaven in August as the second product to leverage SK Biopharm's US direct sales network, has completed patient enrollment for a Phase 2/3 trial (RISE3) in adults with partial-onset seizures, with top-line results expected in the second half of this year. Alongside this, the company is expanding its research and development into oncology, focusing on next-generation modalities including radioligand therapy and targeted protein degradation.

Lee also introduced the company's "AI-Native Operation" strategy — aimed at AI-driven drug discovery and enterprise-wide operational efficiency — as well as a business model called "East-West Bridge," which identifies promising early-stage drug candidates from Asian biotech companies and connects them to global markets through SK Biopharm's clinical development and commercialization capabilities.

"Building on the capabilities we demonstrated through the US commercialization of cenobamate, we have entered a phase of securing new growth engines," Lee said. "We will actively leverage AI and open innovation to accelerate drug development, sharpen our competitiveness and strengthen the foundation for sustainable growth."

Meanwhile, the Korea Biotechnology Industry Organization made its first official appearance at the London Jefferies conference, seeking to expand European investment networks for South Korean biotech companies. Hwang Ju-ri, the organization's head of external affairs, introduced strategies for entering the Korean biomarket at a panel discussion at the Global Frontiers conference during London Life Sciences Week on Monday. The organization also co-hosted a "Korea Night" event with Jefferies on Tuesday, sponsored by SK Biopharm, to facilitate networking between South Korean biotech representatives and overseas institutional investors.

The presentation was significant for laying out a multi-layered growth roadmap before global institutional investors — one that combines expanded indications and formulations for cenobamate, the addition of follow-on drugs and the development of next-generation oncology modalities to reduce the company's dependence on revenue from a single product.


silverpaper@heraldcorp.com